Can frequent digital Check-Ins track how well longevity treatments work?

NCT ID NCT07871799

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 13, 2026 · Last updated Oct 14, 2026 · Updated 1 time

Summary

Researchers at Sheba Medical Center ran a small pilot study to see if repeated digital measurements could track individual responses to healthy-aging interventions. They enrolled 31 adults aged 50 to 80 without diabetes and with a body-mass index of at least 25. Participants received metformin plus either semaglutide or empagliflozin, along with investigational AgeBiotics supplements, and used a smartphone app to submit images, voice recordings, and surveys between clinic visits. The goal was to link these digital patterns to changes in a composite score of muscle, immune, and cognitive function over eight weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of metformin, semaglutide or empagliflozin, and investigational AgeBiotics supplements
What this could lead to
If the digital monitoring approach works, it could help doctors tailor healthy-aging treatments to each person's unique response over time.
What could go wrong
This is a small, short pilot study with only 31 participants. The digital measures may not reliably capture meaningful changes, and the results might not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

31 people

The number who actually took part.

Started

Nov 2025

Finished

Feb 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, aged 50 to 80 years, inclusive. * Generally healthy, as determined by medical history and screening assessments, with no more than 2 stable, well-controlled chronic conditions. * Body-mass index (BMI) ≥25 kg/m². * No diagnosis of Type 1 or Type 2 diabetes mellitus and screening HbA1c \<6.5%. * Willing and able to provide written informed consent prior to any study-related procedures. * Willing and able to comply with all study procedures, including daily use of a compatible smartphone or tablet for app-based digital biomarker data collection and completion of required home study procedures. * If female and of childbearing potential, must be postmenopausal for at least one year. Exclusion Criteria: Metabolic \& Endocrine * Diagnosis of Type 1 or Type 2 diabetes mellitus, or HbA1c ≥6.5% at screening. * History of pancreatitis, medullary thyroid carcinoma (personal or family), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). * History of significant or recurrent hypoglycemia requiring medical intervention. * Known Child-Pugh Class B or C hepatic disease. * BMI \<25 kg/m². Renal \& Genitourinary * Impaired renal function, defined as an estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m² at screening, or a reported renal problem. * History of diabetic ketoacidosis (DKA). * History of recurrent (≥3 in the last 12 months) or severe urinary tract infections or genital mycotic infections. Gastrointestinal * Self-reported history of severe gastrointestinal disease such as gastroparesis, inflammatory bowel disease (Crohn's disease or ulcerative colitis), or chronic malabsorption syndromes; known gallstones; significant hypertriglyceridemia (e.g., triglycerides \>500 mg/dL); or prior biliary tract surgery. * Previous bariatric surgery that may affect drug absorption (e.g., gastric bypass). Cardiovascular * New York Heart Association (NYHA) Class III or IV congestive heart failure. * History of myocardial infarction, unstable angina, or stroke within the 6 months prior to screening. * Symptomatic hypotension or a screening systolic blood pressure consistently \<100 mmHg. Other Medical Conditions * Active malignancy within the last 2 years, with the exception of successfully treated non-melanoma skin cancer or cervical carcinoma in situ. * Known significant active liver disease (e.g., active hepatitis or cirrhosis), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 times the upper limit of normal at screening. * History of lactic acidosis. * Any condition associated with an increased risk of lactic acidosis, such as severe dehydration or acute systemic illness at the time of screening. * Current or recent (within 2 years) diagnosis of anorexia nervosa, bulimia, or another eating disorder. * Current use of known nephrotoxic agents (e.g., high-dose NSAIDs or contrast agents) that may exacerbate renal risk. Concomitant Medications \& Lifestyle * Current use of any other glucose-lowering agents (e.g., insulin, other GLP-1 receptor agonists, DPP-4 inhibitors, or sulfonylureas). * Chronic use of systemic corticosteroids or loop diuretics. Inhaled or topical corticosteroids and stable replacement doses (e.g., hydrocortisone \<20 mg/day) are acceptable. * Participation in another interventional clinical trial within the 3 months prior to screening. * Excessive alcohol consumption, defined as more than 14 standard drinks per week for men or 7 per week for women, or a history of alcohol use disorder. * Known allergy or hypersensitivity to metformin, semaglutide, any SGLT-2 inhibitor, or any of their components or excipients. General * Any condition which, in the opinion of the investigator, would place the participant at undue risk or interfere with the study's conduct or the interpretation of its results. * Cognitive or mental impairment that would prevent the participant from understanding the consent form, adhering to daily tasks, or providing reliable data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy aging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sheba Longevity Center, Sheba Medical Center

    Ramat Gan, Tel Aviv, 5265601, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.